STOCK TITAN

Regulus Therapeu - RGLS STOCK NEWS

Welcome to our dedicated page for Regulus Therapeu news (Ticker: RGLS), a resource for investors and traders seeking the latest updates and insights on Regulus Therapeu stock.

Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical innovator focused on developing microRNA-targeted therapies through advanced oligonucleotide technology. This page serves as the definitive source for official company announcements, research milestones, and regulatory developments.

Investors and researchers will find timely updates on clinical trial progress, including the Phase 1b study of RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD). Our curated news collection provides essential insights into therapeutic advancements, partnership agreements, and strategic initiatives shaping the company's trajectory.

The repository features rigorously verified information across key categories: clinical program updates, financial disclosures, intellectual property developments, and scientific publications. Each entry maintains factual accuracy while highlighting implications for Regulus' position in the precision medicine landscape.

Bookmark this page for direct access to primary source materials from Regulus Therapeutics. Regularly updated content ensures stakeholders maintain current understanding of the company's progress in addressing complex diseases through RNA-targeted therapeutics.

Rhea-AI Summary
Regulus Therapeutics to host virtual investor event on September 6, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.19%
Tags
conferences
-
Rhea-AI Summary
Regulus Therapeutics reports financial results for Q2 2023 and provides corporate update. The Phase 1b MAD study of RGLS8429 for ADPKD is progressing, with dosing of the first patient in the second cohort. The company also strengthened its leadership team with new appointments. Cash position as of June 30, 2023, was $37.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
-
Rhea-AI Summary
Regulus Therapeutics Inc. (Nasdaq: RGLS) will have CEO Jay Hagan presenting at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023, at 11:30 a.m. ET. The live presentation will be available for replay on the company's website for 120 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
conferences
Rhea-AI Summary
Regulus Therapeutics Inc. to present at the H.C. Wainwright 2nd Annual Kidney Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.15%
Tags
none
-
Rhea-AI Summary
Regulus Therapeutics Inc. announced the advancement to the second cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. The company is pleased with the progress and expects topline data from the first cohort by the end of Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
Regulus Therapeu

Nasdaq:RGLS

RGLS Rankings

RGLS Stock Data

136.46M
64.80M
2.18%
82.48%
3.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO